[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343118-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343118-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hspa8-inhibitors-augment-cancer-chemotherapeutic-effectiveness-via-potentiating-necroptosis","HSPA8 inhibitors augment cancer chemotherapeutic effectiveness via potentiating necroptosis","","Pharmacological inhibition of HSPA8 is investigated as a strategy to enhance cancer therapy by amplifying necroptosis. The study evaluates the effects of VER-155008 (nucleotide binding domain targeting) and pifithrin-μ (substrate binding domain targeting) in vitro and in vivo. Results show that HSPA8 inhibitors disrupt HSPA8 binding to RHIM-containing protein fibrils, block HSPA8’s suppression of necroptosis, increase sensitivity to microtubule-targeting agents, reverse chemoresistance, and promote tumor regression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hspa8-inhibitors-augment-cancer-chemotherapeutic-effectiveness-via-potentiating-necroptosis/343118/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hspa8-inhibitors-augment-cancer-chemotherapeutic-effectiveness-via-potentiating-necroptosis/343118.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about HSPA8 inhibitors?","Question",{"text":63,"@type":64},"It asks whether pharmacological inhibition of HSPA8 can promote cancer regression by enabling necroptosis, which had not been explored previously.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the inhibitors work at the molecular level?",{"text":68,"@type":64},"They target HSPA8 to disrupt its binding to RHIM-containing protein fibrils, thereby impeding HSPA8’s regulatory role in RHIM amyloid formation and allowing necroptosis to proceed.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic benefits are demonstrated in vitro and in vivo?",{"text":72,"@type":64},"In vitro, the inhibitors increase cancer cell sensitivity to microtubule-targeting agents and help reverse chemoresistance. In vivo, they facilitate tumor regression by augmenting necroptosis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343118,1790270015,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cell Biology in China  \nMBoC | ARTICLE  \nHSPA8 inhibitors augment cancer chemotherapeutic effectiveness via potentiating necroptosis  \nErpeng Wua, b,*, Chenlu Wua, Kelong Jiaa, Shen’ao Zhouc, and Liming Suna,*,\\#  \naShanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China; bDepartment of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; cCelliver Biotechnology Inc., Shanghai 200030, China  \nABSTRACT Our recent work has uncovered a novel function of HSPA8 as an amyloidase, capable of dismantling the RHIM-containing protein fibrilsto suppress necroptosis. However, the impact of HSPA8 inhibitors on cancer regression via necroptosis remains unexplored. In this study, we conducted a comprehensive investigation to assess the potential of HSPA8 inhibitors in enhancing necroptosis both in vitro and in vivo. Our findings indicate that pharmacologic inhibition of HSPA8, achieved either through VER (VER-155008) targeting the nucleotide binding domain or pifithrin-μ targeting the substrate binding domain of HSPA8, significantly potentiates necroptosis induced by diverse treatments in cellular assays. These inhibitors effectively disrupt the binding of HSPA8 to the RHIM protein, impeding its regulatory function on RHIM amyloid formation. Importantly, HSPA8 inhibitors significantly enhanced cancer cell sensitivity to microtubule-targeting agents (MTAs) in vitro, while reversing chemoresistance and facilitating tumor regression by augmenting necroptosis in vivo. Our findings suggest a promising therapeutic approach to cancer through necroptosis modulation via HSPA8 targeting, particularly in combination with MTA drugs for enhanced treatment efficacy.  \nSIGNIFICANCE STATEMENT  \n• Background: RHIM-amyloids are required for necroptosis. HSPA8, a recently discovered amyloidase, dismantles these fibrils to suppress necroptosis. How pharmacological inhibition of HSPA8 contributes to chemo-induced cancer cell necroptosis is unknown.  \n• Key Results: This study demonstrates that pharmacologic inhibitors targeting HSPA8 significantly enhance necroptosis in cancer cells. By blocking HSPA8’s activity, these inhibitors potentiate the effects of cancer treatments, reversing chemoresistance and promoting tumor regression.  \n• Implications: Targeting HSPA8 through pharmacologic inhibitors offers a promising therapeutic strategy for cancer treatment. This approach could be particularly effective in combination with MTAs, leading to enhanced treatment efficacy.  \nMonitoring Editor  \nGuangshuo Ou Tsinghua University  \nReceived: Apr 30, 2024  \nRevised: Jun 17, 2024  \nAccepted: Jun 24, 2024  \nThis article was published online ahead of print in MBoC in Press ([http://www](http://www). [molbiolcell.org/cgi/doi/10.1091/mbc.E24-04-0194](molbiolcell.org/cgi/doi/10.1091/mbc.E24-04-0194)) on July 11, 2024.  \nAuthor contributions: L.S. and E.W. conceived and designed the experiments;  \nL.S., E.W., K.J., C.W., and S.Z. analyzed the data; L.S. and E.W. drafted the article; L.S. and E.W. prepared the digital images; E.W., K.J., C.W., and S.Z. performed the experiments.  \n\\#Lead Corresponding Author: Liming Sun, Ph. D.  \n*Address correspondence to: Erpeng Wu ([wuerpeng6@sibcb.ac.cn](wuerpeng6@sibcb.ac.cn)); Liming Sun ([liming.sun@sibcb.ac.cn](liming.sun@sibcb.ac.cn)) .  \nAbbreviations used: DAI, DNA dependent activator of interferon regulatory factors; MTAs, microtubule-targeting agents; NBD, nucleotide binding domain;  \nRHIM, RIP homotypic interaction motif; RIP1, receptor-interacting serine/threonine-protein kinase 1; RIP3, receptor-interacting serine/threonine-protein kinase 3; SBD, substrate binding domain; TRIF, TIR-domain-containing adapter-inducing interferon-β .  \n© 2024 Wu et al. This article is distributed by The American Society for Cell Biology under li","cbCainkcqxkEnzDN","https://ap.wps.com/l/cbCainkcqxkEnzDN","pdf",1547565,"English","# Abstract\n# Significance Statement\n## Background\n## Key Results\n## Implications\n# Introduction\n# Results (inferred from study focus)\n## HSPA8 inhibitor effects on necroptosis\n## Mechanistic disruption of HSPA8–RHIM interaction\n## Impact on sensitivity to microtubule-targeting agents\n## Effects on chemoresistance and tumor regression","[{\"question\":\"What question does the study address about HSPA8 inhibitors?\",\"answer\":\"It asks whether pharmacological inhibition of HSPA8 can promote cancer regression by enabling necroptosis, which had not been explored previously.\"},{\"question\":\"How do the inhibitors work at the molecular level?\",\"answer\":\"They target HSPA8 to disrupt its binding to RHIM-containing protein fibrils, thereby impeding HSPA8’s regulatory role in RHIM amyloid formation and allowing necroptosis to proceed.\"},{\"question\":\"What therapeutic benefits are demonstrated in vitro and in vivo?\",\"answer\":\"In vitro, the inhibitors increase cancer cell sensitivity to microtubule-targeting agents and help reverse chemoresistance. In vivo, they facilitate tumor regression by augmenting necroptosis.\"}]","HSPA8 inhibitors augment cancer chemotherapeutic effectiveness via potentiating necroptosis | PDF",1790049974,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab2a4baac0298121ffd861126826485b.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9fbb7a98f41c55ca719b4d6ae3f984f.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f1fe178202c759ee9e23897dc4ccf5d.webp",981,1312,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0cc29b856977129cd71019b75249c7af.webp",980,1311]